JPWO2023283619A5 - - Google Patents
Info
- Publication number
- JPWO2023283619A5 JPWO2023283619A5 JP2024500480A JP2024500480A JPWO2023283619A5 JP WO2023283619 A5 JPWO2023283619 A5 JP WO2023283619A5 JP 2024500480 A JP2024500480 A JP 2024500480A JP 2024500480 A JP2024500480 A JP 2024500480A JP WO2023283619 A5 JPWO2023283619 A5 JP WO2023283619A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- optionally
- complex
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220030P | 2021-07-09 | 2021-07-09 | |
| US63/220,030 | 2021-07-09 | ||
| PCT/US2022/073534 WO2023283619A2 (en) | 2021-07-09 | 2022-07-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024525612A JP2024525612A (ja) | 2024-07-12 |
| JPWO2023283619A5 true JPWO2023283619A5 (https=) | 2025-07-17 |
| JP2024525612A5 JP2024525612A5 (https=) | 2025-07-17 |
Family
ID=84802094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500480A Pending JP2024525612A (ja) | 2021-07-09 | 2022-07-08 | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240382609A1 (https=) |
| EP (1) | EP4367142A4 (https=) |
| JP (1) | JP2024525612A (https=) |
| KR (1) | KR20240032946A (https=) |
| CN (1) | CN118401553A (https=) |
| CA (1) | CA3226300A1 (https=) |
| IL (1) | IL309911A (https=) |
| WO (1) | WO2023283619A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| IL309936A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008317566B2 (en) * | 2007-10-26 | 2014-05-01 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| EP3829595A4 (en) * | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| IL312067B2 (en) * | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
| KR20230044242A (ko) * | 2020-07-23 | 2023-04-03 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 |
-
2022
- 2022-07-08 CA CA3226300A patent/CA3226300A1/en active Pending
- 2022-07-08 JP JP2024500480A patent/JP2024525612A/ja active Pending
- 2022-07-08 IL IL309911A patent/IL309911A/en unknown
- 2022-07-08 EP EP22838590.2A patent/EP4367142A4/en active Pending
- 2022-07-08 US US18/577,472 patent/US20240382609A1/en active Pending
- 2022-07-08 WO PCT/US2022/073534 patent/WO2023283619A2/en not_active Ceased
- 2022-07-08 CN CN202280060769.5A patent/CN118401553A/zh active Pending
- 2022-07-08 KR KR1020247004294A patent/KR20240032946A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309912A (en) | Muscle targeting complexes and their uses for the treatment of dystrophinopathy | |
| JPWO2023283624A5 (https=) | ||
| JPWO2023283615A5 (https=) | ||
| JPWO2023283613A5 (https=) | ||
| JPWO2023283619A5 (https=) | ||
| JP7803926B2 (ja) | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 | |
| JPWO2023283614A5 (https=) | ||
| US11771776B2 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| US20240117356A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US20240216522A1 (en) | Muscle targeting complexes and uses thereof for treating friedreich's ataxia | |
| CA3226301A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| JPWO2022020107A5 (https=) | ||
| JPWO2021142307A5 (https=) | ||
| IL309936A (en) | Muscle targeting complexes and formulations for the treatment of dystrophinopathy | |
| IL294480A (en) | Muscle-oriented complexes and their uses for the treatment of atrophy of the muscles of the face, shoulder blades, and arms | |
| JP2026503873A (ja) | Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用 | |
| IL315944A (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| KR20240095330A (ko) | 디스트로핀병증을 치료하기 위한 근육 표적화 복합체 | |
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy | |
| IL322946A (en) | Methods and compositions for inhibiting the progression of intramuscular fibrosis | |
| JPWO2021142234A5 (https=) |